With a market capitalization (market cap) of $9.14B — a measure of how much the company is worth — Immunovant, Inc. is the 1008th most valuable company in Healthcare as of August 18, 2026. Shares trade at $44.30, up +1.35% on the day.
of 2,587
price ÷ annual EPS
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
FY 2026
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Visit websiteAs of August 18, 2026, Immunovant, Inc. (IMVT) is worth $9.14B — this is its market capitalization, the total value of all its outstanding shares.
Immunovant, Inc.’s market cap is $9.14B, which ranks it #1008 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Immunovant, Inc. (IMVT) shares trade at $44.30, up 1.35% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2026